Saturday 17 October 2026
Export BPTH’s income statement to Excel — free account
Bio-Path Holdings, Inc.
BPTH Healthcare Biotechnology
In the quarter to March 2026, EPS fell 101.2% and free cash flow grew 98.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow BPTH
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — | — |
P/S ratio |
0.00 | 0.00 | — | — | — | — | — | — | — |
Altman Z-Score |
13.97 | 6.86 | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(5.91) | (5.58) | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — | — |
P/Operating CF |
(72.00) | (9.51) | — | — | — | — | — | — | — |
P/B ratio |
14.08 | 2.62 | — | — | — | — | — | — | — |
Price to Tangible BV |
15.87 | 2.90 | — | — | — | — | — | — | — |
EV/Sales |
0.00 | 0.00 | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | — | — | — | — | — | — |
EV/Operating CF |
(13.09) | (1.91) | — | — | — | — | — | — | — |
EV/FCF |
(12.39) | (1.79) | — | — | — | — | — | — | — |
Quick Ratio |
8.93 | 7.54 | 0.76 | 16.42 | 11.77 | 24.82 | 6.17 | 0.55 | 0.36 |
Current Ratio |
10.15 | 9.40 | 1.61 | 17.68 | 13.65 | 27.29 | 9.27 | 1.60 | 1.15 |
Net Debt/EBITDA |
1.13 | 0.70 | 0.12 | 2.41 | 1.28 | 2.31 | 0.76 | 0.07 | 0.10 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.21 | 0.99 | 0.71 | 0.97 | 1.01 | 0.95 | 1.09 | 0.72 | 1.07 |
Capex/Depreciation |
(1.66) | (1.31) | (0.04) | 0.00 | 0.00 | (0.43) | (0.12) | 0.00 | 0.00 |
| (74.76%) | (98.87%) | (184.88%) | (77.11%) | (60.19%) | (51.52%) | (69.99%) | (220.02%) | (3,325.71%) | |
| (58.82%) | (76.57%) | (150.54%) | (68.23%) | (55.61%) | (48.51%) | (65.20%) | (167.56%) | (278.59%) | |
ROIC |
0.00% | (266.59%) | (2,508.76%) | (823.20%) | (518.44%) | (387.81%) | (229.24%) | 0.00% | 0.00% |
Return on Tangible Assets |
(66.07%) | (110.45%) | (704.68%) | (40.85%) | (72.46%) | (41.09%) | (98.43%) | (1,326.57%) | (1,963.10%) |
Average Days of Receivables |
0.00 | 0.00 | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
42,107.69% | 14,810.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
23,184.62% | 9,521.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6,030.77% | 2,143.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.06 | 0.31 | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(5.92%) | (35.64%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(7.42%) | (40.15%) | — | — | — | — | — | — | — |
Revenue per Share |
0.56 | 1.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(351.21) | (315.75) | (204.82) | (62.91) | (56.96) | (29.49) | (41.49) | (24.13) | (4.40) |
Capex per Share |
(14.57) | (21.35) | (0.57) | 0.00 | 0.00 | (0.21) | (0.06) | 0.00 | 0.00 |
Free Cash Flow per Share |
(365.78) | (337.10) | (205.38) | (62.91) | (56.96) | (29.70) | (41.55) | (24.13) | (4.40) |
Cash per Share |
404.09 | 236.71 | 33.58 | 153.69 | 71.49 | 70.69 | 28.53 | 2.20 | 0.49 |
Shareholders Equity per Share |
355.17 | 320.12 | 40.74 | 158.66 | 78.33 | 75.70 | 38.94 | 0.92 | 0.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
355.17 | 320.12 | 40.74 | 158.66 | 78.33 | 75.70 | 38.94 | 0.92 | 0.06 |
Free Cash Flow |
(8.49) | (8.49) | (6.14) | (8.36) | (10.96) | (9.99) | (15.12) | (11.53) | (10.57) |
Working Capital |
9.60 | 6.64 | 0.81 | 20.75 | 14.79 | 25.18 | 13.93 | 1.14 | 0.48 |
Capital Expenditures |
(0.34) | (0.54) | (0.02) | — | — | (0.07) | (0.02) | — | — |
Net Current Asset Value |
6.70 | 6.64 | 0.81 | 20.42 | 14.55 | 25.03 | 13.82 | 0.26 | 0.05 |
EV/EBIT |
0.00 | 0.00 | — | — | — | — | — | — | — |
Capex to Sales |
26.00 | 14.54 | 0.00 | — | — | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.33 | 0.63 | 1.05 | 0.76 | 0.65 | 0.72 | 1.13 | 2.34 | 6.91 |
Cash ROIC |
(48.17%) | (60.54%) | (276.37%) | (20.14%) | (38.02%) | (20.29%) | (61.58%) | (772.61%) | (796.91%) |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Payables |
0.06 | 0.06 | 0.32 | 0.54 | 0.29 | 0.10 | 0.39 | 0.56 | 0.87 |
Average Assets |
11.48 | 10.53 | 5.70 | 12.60 | 19.57 | 21.52 | 21.27 | 9.60 | 3.55 |
Average Common Equity |
9.03 | 8.15 | 4.64 | 11.15 | 18.08 | 20.26 | 19.82 | 7.31 | 0.30 |
Columns are period end dates